Abstract
In this paper an overview of the activities since 1982 of the EORTC Lung Cancer Cooperative Group is given. Although the last decade has brought only small improvements, several important questions have been answered. Prognostic factors, optimal duration of chemotherapy, retreatment policies, non-cross resistant combinations and chemotherapy of brain metastases have been the subject of cooperative effort during the last ten years, allowing better choices to be made in the treatment of individual patients. Currently the place and timing of radiotherapy and the efficacy of several new drugs are under study. In order to assess reliably the relatively small gains of different treatment options, cooperative groups like the EORTC LCCG will continue to play an important role in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
